Xtacy Therapeutics Corp.
Pegasus Mercantile Inc. is an incubator, venture capital firm specializing in incubation, startup and early stage. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques … Read more
Xtacy Therapeutics Corp. (XTCYF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.000x
Based on the latest financial reports, Xtacy Therapeutics Corp. (XTCYF) has a cash flow conversion efficiency ratio of 0.000x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($0.00) by net assets ($-368.72K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xtacy Therapeutics Corp. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Xtacy Therapeutics Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xtacy Therapeutics Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xtacy Therapeutics Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
0.001x |
|
PetVivo Holdings Inc. Warrant
NASDAQ:PETVW
|
-0.525x |
|
First Berlin Bancorp Inc.
OTCMKTS:FTFI
|
N/A |
|
CLAS OHLSON -B-
BE:OHCB
|
0.208x |
|
Sensor Technologies Corp
PINK:MOOIF
|
0.019x |
|
Origen Resources Inc
PINK:OGGNF
|
-0.092x |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
0.087x |
|
TenX Protocols Inc.
V:TNX
|
N/A |
Annual Cash Flow Conversion Efficiency for Xtacy Therapeutics Corp. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Xtacy Therapeutics Corp. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $-448.20K | $-116.40K | 0.260x | -12.57% |
| 2023-09-30 | $-271.68K | $-80.70K | 0.297x | -68.74% |
| 2022-09-30 | $-448.66K | $-426.30K | 0.950x | +399.20% |
| 2021-09-30 | $-517.22K | $-98.45K | 0.190x | -19.27% |
| 2020-09-30 | $-260.65K | $-61.46K | 0.236x | -- |